NXY-059 for the treatment of acute stroke: Pooled analysis of the SAINT I and II trials

Stroke

Volumn 39, Issue 6, 2008, Pages 1751-1758

  Diener, Hans Christoph ^a   Lees, Kennedy R ^b   Lyden, Patrick ^c   Grotta, Jim ^d   Davalos, Antoni ^e   Davis, Stephen M ^f   Shuaib, Ashfaq ^g   Ashwood, Tim ^h   Wasiewski, Warren ⁱ   Alderfer, Vivian ⁱ   Hårdemark, Hans Goran ^h   Rodichok, Larry ^i,j  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Department of Medicine and Therapeutics   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Stroke Center   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ ASTRAZENECA R AND D   (Sweden)

^j ASTRAZENECA   (United Kingdom)

more..

Author keywords

Ischemic stroke; Neuroprotective therapy; Pooled analysis; Predictors of outcome; Thrombolysis

Indexed keywords

ALTEPLASE; DISUFENTON SODIUM; ANTIOXIDANT; BENZENESULFONIC ACID DERIVATIVE; NEUROPROTECTIVE AGENT; PLACEBO;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RISK FACTOR; STROKE; AGE; BRAIN; BRAIN INFARCTION; BRAIN ISCHEMIA; COMORBIDITY; DRUG ADMINISTRATION; DRUG EFFECT; EMERGENCY HEALTH SERVICE; ENCEPHALITIS; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; TREATMENT FAILURE;

AGE FACTORS; AGED; ANTIOXIDANTS; BENZENESULFONATES; BRAIN; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; COMORBIDITY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EMERGENCY MEDICAL SERVICES; ENCEPHALITIS; FEMALE; HUMANS; HYPERGLYCEMIA; INJECTIONS, INTRAVENOUS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PLACEBOS; PROGNOSIS; STROKE; TREATMENT FAILURE;

EID: 46249131138     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.503334     Document Type: Article

References (33)

1. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick J, Brott T, Frankel M, Grotta J, Haley EJ, Kwiatkowski T, Levine S, Lewandowski C, Lu M, Lyden P, Marler J, Patel S, Tilley B, Albers G, Bluhmki E, Wilhelm M, Hamilton S, ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768 -774.
2. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477.
3. Green AR, Shuaib A. Therapeutic strategies for the treatment of stroke. Drug Discovery Today. 2006;11:681-693.
4. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
5. Lees KR, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Ashwood T, Hardemark HG, Wasiewski W, Emeribe U, Zivin JA. Additional outcomes and subgroup analyses of NXY-059 for acute is-chemic stroke in the SAINT I trial. Stroke. 2006;37:2970-2978.
6. Shuaib A, Lees K, Lyden P, Grotta J, Davalos A, Davis S, Diener HC, Ashwood T, Wasiewski W, Emeribe U, for the SAINT II Investigators. NXY-059 for acute ischaemic stroke: results of the SAINT II trial. N Engl J Med. 2007;357:562-571.
7. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864- 870.
8. Cockroft DW, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:864-870.
9. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25:2220 -2226.
10. van Swieten J, Koudstaal P, Visser M, Schouten H, van Gijn J. Interob-server agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
11. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-65.
12. Quinn T, Lees K, Hardemark H, Dawson J, Walters M. Initial experience of a digital training resource for modified Rankin scale assessment in clinical trials. Stroke. 2007;38:2257-2261.
13. Lyden P, Lu M, Jackson C, Marler J, Kothari R, Brott T, Zivin J. Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators. Stroke. 1999;30:2347-2354.
14. Stokes ME, Davis C, Koch GG. Categorial Data Analysis Using the SAS System. Cary, NC: SAS Institute Inc; 2000.
15. Young FB, Lees KR, Weir CJ. Improving trial power through use of prognosis-adjusted end points. Stroke. 2005;36:597-601.
16. Weimar C, Ho TW, Katsarava Z, Diener HC. Improving patient selection for clinical acute stroke trials. Cerebrovasc Dis. 2006;21:386 -392.
17. Weimar C, Konig IR, Kraywinkel K, Ziegler A, Diener HC. Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models. Stroke. 2004;35:158-162.
18. Schillinger T, Kluger W, Exner M, Mlekusch W, Sabeti S, Amighi J, Wagner O, Minar E, Schillinger M. Dental and periodontal status and risk for progression of carotid atherosclerosis: the inflammation and carotid artery risk for atherosclerosis study dental substudy. Stroke. 2006;37:2271-2276.
19. Waje-Andreassen U, Krakenes J, Ulvestad E, Thomassen L, Myhr KM, Aarseth J, Vedeler CA. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand. 2005;111:360-365.
20. Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, Lyden PD, Broderick JP, Kwiatkowski TG, Fineberg SE, NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002;59:669-674.
21. Woo E, Chan YW, Yu YL, Hunag CY. Admission glucose levels in relation to mortality and morbidity outcome in 252 stroke patients. 1988;19:185-191.
22. Sanossian N, Saver JL, Rajajee V, Selco SL, Kim D, Razinia T, Ovbiagele B. Premorbid antiplatelet use and ischemic stroke outcomes. Neurology. 2006;66:319-323.
23. Leonardi-Bee J, Bath P, Phillips S, Sandercock P, IST Collaborative Group. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke. 2002;33:1315-1320.
24. Yong M, Diener HC, Kaste M, Mau J. Characteristics of blood pressure profiles as predictors of long-term outcome after acute ischemic stroke. Stroke. 2005;36:2619-2625.
25. Wahlgren NG, MacMahon DG, De Keyser J, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis. 1994;4:204 -210.
26. Asahi M, Asahi K, Wang X, Lo EH. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2000;20:452-457.
27. Lapchak PA. Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep. 2002;2:38-43.
28. Fisher M, Stroke Therapy Academic Industry Roundtable. Recommendations for advancing development of acute stroke therapies: stroke therapy academic industry roundtable 3. Stroke. 2003;34:1539-1546.
29. Fisher M, Albers GW, Donnan GA, Furlan AJ, Grotta JC, Kidwell CS, Sacco RL, Wechsler LR. Enhancing the development and approval of acute stroke therapies: stroke therapy academic industry roundtable. Stroke. 2005;36:1808-1813.
30. Fisher M, Hanley DF, Howard G, Jauch EC, Warach S. Recommendations from the STAIR V meeting on acute stroke trials, technology, and outcomes. Stroke. 2007;38:245-248.
31. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752-2758.
32. Marshall JW, Cummings RM, Bowes LJ, Ridley RM, Green AR. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke. 2003;34:2228 -2233.
33. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol. 2007;205:20-25.